Changes in miR-143 and miR-21 expression and clinicopathological correlations in pancreatic cancers

Pancreas

Volumn 41, Issue 8, 2012, Pages 1280-1284

  Tavano, Francesca ^a   Di Mola, Francesco Fabio ^a   Piepoli, Ada ^b   Panza, Anna ^b   Copetti, Massimiliano ^c   Burbaci, Francesca Paola ^a   Latiano, Tiziana ^a   Pellegrini, Fabio ^c,d   Maiello, Evaristo ^a   Andriulli, Angelo ^b   Di Sebastiano, Pierluigi ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Division of Gastroenterology   (Italy)

^c Unit of Biostatistics   (Italy)

^d Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

lymph nodes spreading; microRNA expression; pancreatic cancer; pancreatic tumor marker

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA 143; MICRORNA 21;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868302145     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31824c11f4     Document Type: Article

References (31)

1. di Mola FF, di Sebastiano P. Pain and pain generation in pancreatic cancer. Langenbecks Arch Surg. 2008;393(6):919-922.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Fischer HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004;11:301-309.
4. Hirata K, Egawa S, Kimura Y, et al. Current status of surgery for pancreatic cancer. Dig Surg. 2007;24:137-147.
5. Freitas D, Dos Santos Fernandes GM, Hoff P, et al. Medical management of pancreatic adenocarcinoma. Pancreatology. 2009;9:223-232.
6. Alexiev BA, Drachenberg CB, Papadimitriou JC. Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behaviour. Diagnostic Pathology. 2007;2:28.
7. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008;19(4):282-288.
8. Bartel DP. MicroRNA's: genomics biogenesis, mechanism, and function. Cell. 2004;116:281-297.
9. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukaemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529.
10. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer new paradigms in molecular oncology. Curr Opin Cell Biol. 2009;21:470-479.
11. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999-3004.
12. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261.
13. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-866.
14. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 2007;26:311-320.
15. Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77:12-21.
16. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009;13(1):39-53.
17. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26:4442-4452.
18. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-1908.
19. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24:4677-4684.
20. Slaby O, Svoboda M, Fabiana P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72:397-402.
21. Mardin WA, Mees ST. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol. 2009;16:3183-3189.
22. Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12:2171-2176.
23. Moriyama T, Ohuchida K, Mizumoto K, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009;8(5):1067-1074.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
25. Sakata J, Shirai Y, Wakai T, et al. Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol. 2007;33:346-351.
26. House MG, Gonen M, Jarnagin WR, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549-1555.
27. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704-709.
28. Klapdor R, Aronsson AC, Duffy MJ, et al. Tumor markers in gastrointestinal cancers, EGTM recommendations. Anticancer Res. 1999;19:2785-2820.
29. Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13(11):2050-2058.
30. Saad ED, Reis PT, Borghesi G, et al. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. Rev Assoc Med Bras. 2010;56(1):22-26.
31. Zhang S, Wang YM, Sun CD, et al. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol. 2008;14(23):3750-3753.